



Marc Fisher, MD
Editor-in-Chief
Stroke: A Journal of Cerebral Circulation

Authorization of publication STROKE/2019/026545R1

Dear Dr. Fisher,

On behalf of Bayer I hereby authorize the publication of the article
"Leveraging human genetics to estimate clinical risk reductions
achievable by inhibiting Factor XI" (STROKE/2019/026545R1) in Stroke.

Best regards,

Bayer AG



Dr. Karl Ziegelbauer
SVP Open Innovation & Digital Technologies



26. Juli 2019

Karl Ziegelbauer

Bayer AG
Pharmaceuticals
Open Innovation & Digital
Technologies

Postadresse:
Building 402, R. 308
Aprather Weg 18a
42113 Wuppertal
Germany

Tel. +49 202 36-5293
karl.ziegelbauer@bayer.com

www.bayer.com

Vorstand:
Werner Baumann, Vorsitzender
Liam Condon
Johannes Dietsch
Hartmut Klusik
Kemal Malik
Erica Mann
Heiko Schipper
Dieter Weinand

Vorsitzender des Aufsichtsrats:
Werner Wenning

Sitz der Gesellschaft:
Leverkusen
Amtsgericht Köln
HRB 48248